506U78 in Treating Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma - Contacts and Locations

506U78 in Treating Patients With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

This study has been completed.

Study NCT00003837. Last updated on July 23, 2008. Information provided by National Cancer Institute (NCI)

Please refer to this study by its ClinicalTrials.gov identifier: NCT00003837

Locations


United States, California
	City of Hope Comprehensive Cancer Center
	Duarte, California, United States, 91010-3000

United States, Florida
	H. Lee Moffitt Cancer Center and Research Institute at University of South Florida
	Tampa, Florida, United States, 33612

United States, Maryland
	NCI - Pharmaceutical Management Branch
	Bethesda, Maryland, United States, 20892

United States, Michigan
	Barbara Ann Karmanos Cancer Institute
	Detroit, Michigan, United States, 48201-1379

United States, Minnesota
	Mayo Clinic Cancer Center
	Rochester, Minnesota, United States, 55905

United States, Ohio
	Case Comprehensive Cancer Center
	Cleveland, Ohio, United States, 44106-5047

United States, Pennsylvania
	Abramson Cancer Center of the University of Pennsylvania
	Philadelphia, Pennsylvania, United States, 19104-4283

Sponsors and Collaborators

National Cancer Institute (NCI)

Investigators


Study Chair:	Anthony J. Murgo, MD	NCI - Investigational Drug Branch